Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.
Alemtuzumab is a powerful lymphocyte depleting antibody currently being evaluated in solid organ transplantation. This paper describes 5-year results of a single center study of alemtuzumab as induction in renal transplantation. Thirty-three renal transplant recipients received 20 mg alemtuzumab on...
主要な著者: | Watson, C, Bradley, J, Friend, P, Firth, J, Taylor, C, Bradley, JR, Smith, K, Thiru, S, Jamieson, N, Hale, G, Waldmann, H, Calne, R |
---|---|
フォーマット: | Journal article |
言語: | English |
出版事項: |
2005
|
類似資料
-
Campath 1H (alemtuzumab) in renal transplantation: 5-year comparative follow up.
著者:: Watson, C, 等
出版事項: (2004) -
Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients.
著者:: Calne, R, 等
出版事項: (1999) -
Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up.
著者:: Clatworthy, MR, 等
出版事項: (2009) -
CAMPATH-1 FOLLOWING RENAL-TRANSPLANTATION - A RANDOMIZED TRIAL
著者:: Friend, P, 等
出版事項: (1988) -
Reversal of allograft rejection using the monoclonal antibody, Campath-1G.
著者:: Friend, P, 等
出版事項: (1991)